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Abstract People with type 2 diabetes have an increased risk
of cardiovascular disease (CVD). Multivariate cardiovascular
risk scores have been used in many countries to identify
individuals who are at high risk of CVD. These risk scores
include those originally developed in individuals with
diabetes and those developed in a general population. This
article reviews the published evidence for the performance of
CVD risk scores in diabetic patients by: (1) examining the
overall rationale for using risk scores; (2) systematically
reviewing the literature on available scores; and (3) exploring
methodological issues surrounding the development, valida-
tion and comparison of risk scores. The predictive perfor-
mance of cardiovascular risk scores varies substantially
between different populations. There is little evidence to
suggest that risk scores developed in individuals with diabetes
estimate cardiovascular risk more accurately than those
developed in the general population. The inconsistency in
the methods used in evaluation studies makes it difficult to
compare and summarise the predictive ability of risk scores.
Overall, CVD risk scores rank individuals reasonably accu-
rately and are therefore useful in the management of diabetes
with regard to targeting therapy to patients at highest risk.
However,due totheuncertaintyinestimationoftruerisk,care
is needed when using scores to communicate absolute CVD
risk to individuals.
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Abbreviations
AIC Akaike’s information criterion
aROC Area under the receiver operating characteristic
curve
BIC Bayesian information criterion
CVD Cardiovascular disease
DECODE Diabetes Epidemiology: Collaborative Analysis
of Diagnostic Criteria in Europe
FPG Fasting plasma glucose
IDI Integrated discrimination improvement
NRI Net reclassification improvement
PROCAM Prospective Cardiovascular Münster
ROC Receiver operating characteristic curve
SCORE Systematic Coronary Risk Evaluation
UKPDS UK Prospective Diabetes Study
Introduction
Type 2 diabetes is a strong risk factor for cardiovascular
disease (CVD), with some studies suggesting that it confers
an equivalent risk to having had a myocardial infarction [1,
2]. Multifactorial interventions, such as the Steno-2 study,
have been effective in reducing the risk of non-fatal [3] and
fatal CVD [4] among diabetic patients through therapy
targeting hyperglycaemia, hypertension and hypercholester-
olaemia. Despite this evidence of effectiveness, many
countries use a rationing approach to the prescription of
cardiovascular risk reduction treatment, with national
guidelines suggesting that patients should have their risk
of CVD calculated, to ensure therapy is targeted to patients
at highest absolute risk. Multivariate risk scores have,
therefore, been used to predict CVD risk in individuals with
diabetes.
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DOI 10.1007/s00125-009-1454-0There are a large number of scores for the general
population, but few that are specific to people with
diabetes. Whether general population scores can accurately
be used in a subgroup of individuals with diabetes is
unclear [5, 6]. The most commonly used score is that
originally developed in 5,573 men and women participating
in the Framingham study in the early 1970s, which, in
general, performs well in North America [7], but less well
in other populations [7–9] .W ea i m e dt or e v i e wt h e
published evidence on performance of CVD risk scores in
diabetic populations. First, we examined the overall
rationale for using cardiovascular risk scores in patients
with diabetes. Second, we provide results from a systematic
review of the published literature on CVD risk scores that
have been developed or evaluated in individuals with
diabetes. Finally, we explored methodological issues
surrounding the development, validation and comparison
of risk scores.
Why estimate CVD risk in individuals with diabetes?
There are several reasons why it may be important to
quantify the risk of developing CVD in patients with
diabetes. The clear identification of the rationale for
developing a risk score is critical to how its validity is
assessed. For example, if the purpose of a score is to rank
individuals and groups according to absolute risk for the
purpose of targeting therapy to those at greatest risk, then it
is the ranking that is important and not necessarily the
absolute risk estimate. If, on the other hand, the principal
justification is to provide prognostic information or accu-
rate estimation of the likely absolute benefit from a
therapeutic intervention, then a precise computation of
absolute risk is important. Finally, if the main reason for
calculating risk as part of a preventive strategy is to
motivate patients to change their behaviour and adhere to
medical treatments, it may be important to calculate
modifiable risk rather than use a score dominated by fixed
variables. In the following sections we describe the origin
of CVD risk scores and illustrate how purpose, construction
and validation are often disconnected.
CVD risk scores have been widely used in the UK
and elsewhere for over 10 years and were introduced at
a time when the cost of cholesterol-lowering drugs was
an important political issue [10]. National recommenda-
tions began appearing in the mid-1990s, when specified
annual CVD risk estimates were used to determine
thresholds for prescribing therapy. These thresholds were
decided on the basis of the number needed to treat to
prevent one CHD event, the cost-effectiveness of treat-
ment and, predominantly, the proportion of the population
requiring treatment and the total cost of treatment [11]. As
such, the threshold for intervention based on the ranking
of absolute risk was largely a financial decision. Although
results from the Heart Protection Study [12]a n dt h e
Collaborative Atorvastatin Diabetes Study [13] suggest
that statin therapy is effective in patients with diabetes at
high CVD risk, irrespective of their initial cholesterol
concentrations, not all health systems can afford such a
policy. The ranking of absolute risk is clearly important
for making collective decisions about therapy, but, beyond
statin prescribing, does the calculation of CVD risk aid
clinical decision-making?
An estimate of absolute risk can inform the potential for
absolute risk reduction, providing patients with an idea of
expected benefit from a therapy or intervention. This is
important for individual, rather than collective, decision-
making. However, further research is needed to understand
the process by which the clinician and patient interact once
cardiovascular risk has been assessed [9]. While it is
assumed that telling individuals their CVD risk is a
motivating tool, there is only weak evidence that this
assumption is valid. In a systematic review of randomised
controlled trials that evaluated the effectiveness of risk-
scoring methods, no strong evidence was found that a CVD
risk assessment by a clinician improved CVD-related health
outcomes [9]. Practitioners need to provide information
about what patients can do to reduce this risk; they also
need to acknowledge the possibility of false reassurance or
a fatalistic response, both of which can in theory lead to an
increase in population risk. Qualitative work has demon-
strated that very few patients with type 2 diabetes
understand the direct link between having diabetes and
their CVD risk [14]. Although they are aware of CVD, they
are more likely to attribute it to external or immutable
factors such as stress and heredity, rather than modifiable
risk factors such as high cholesterol, hyperglycaemia and
smoking [14]. This phenomenon links in with the idea of
using risk scores as preventive or motivating tools. Most of
the predictive value of a CVD risk score comes from the
inclusion of two unchangeable risk factors, age and sex. It
is probably difficult to persuade patients to change their
behaviour on the basis of CVD risk scores that are mostly
driven by risk factors patients cannot change. Thus risk
scores that only incorporate modifiable risk factors are
more likely to be useful for preventive strategies in patients
with diabetes.
Systematic review of CVD risk assessment tools
Search strategy
A comprehensive literature search for studies of CVD
risk assessment tools was performed using MEDLINE,
2002 Diabetologia (2009) 52:2001–2014Web of Science and Cochrane Reviews from database
inception up to 30 June 2008. The search strategy
focused on four key elements: CVD, type 2 diabetes,
risk assessment/score/prediction and specific names of
k n o w nr i s ks c o r e s( s e eAppendix). We also screened the
reference lists of papers identified from the initial
electronic search. No language restriction was applied;
articles were translated when necessary.
Selection criteria
We included studies reporting CVD risk assessment
tools or scores that: (1) were derived from prospective
cohort studies or randomised trials; (2) were derived in
the general population and evaluated in individuals with
diabetes, or developed in a diabetic population; and (3)
reported a measure of performance of the risk score for
predicting CVD. We restricted the review to studies
that reported the following diseases as a primary
outcome:
& Fatal or non-fatal CVD
& Fatal or non-fatal CHD
& Fatal or non-fatal cerebrovascular disease or stroke
We excluded studies that derived cardiovascular risk
scores for the general population but did not evaluate
them in individuals with diabetes. We excluded studies
that derived risk prediction tools other than score-type
tools, such as those using carotid ultrasonography and
myocardial perfusion scintigraphy. If scores and their
evaluation were reported in several different papers, we
included the score only once by selecting the paper that
reported the most information on predictive ability.
Data extraction
T w or e v i e w e r s( P .C h a m n a n ,R .K .S i m m o n s )i n d e p e n -
dently reviewed the results from the primary search of
titles, followed by the abstract and full paper searches
(Fig. 1). Where reviewers disagreed, consensus was
reached through discussion. The two reviewers used a
standardised form to extract data on the performance of
the risk scores. This included the name of the risk score
and study, the country and setting, details on derivation
and validation populations, follow-up for derivation and
validation cohorts, definition of diabetes and CVD, risk
factors included in the scores, and measures of predictive
ability, including discrimination, calibration, sensitivity,
specificity, and positive and negative predictive value. We
also extracted data from original studies if articles
identified through the initial search did not contain
information on the development or validation of risk
scores (Tables 1 and 2).
Results
Our electronic search retrieved 2,113 potentially relevant
papers (Fig. 1). After reviewing titles, abstracts, full texts
and citation lists, 13 articles reporting the predictive
performance of 17 different CVD risk scores met the
inclusion criteria. We provide a summary of the derivation
of the risk scores in Tables 1 and 2, and a summary
describing the evaluation of the scores in Table 3. One
paper was translated.
Development of risk scores
Out of 17 different risk scores, 15 were developed in
predominantly white populations (USA and Europe) and
two were developed in Chinese populations (Hong Kong).
Cohort size ranged from 1,500 [15] to 205,178 individuals
[16] and follow-up time from 4.7 [17] to 25 years [16]. The
age of men and women included in development cohorts
ranged from 18 to 84 years; patients with previous CVD
were usually excluded. Eight risk scores were originally
developed in a cohort of individuals with diabetes (Table 1),
while the other nine were developed in a general population
and subsequently evaluated in a cohort of individuals with
diabetes (Table 2). The majority of risk scores (n=10)
provided estimates of risk for CHD. Two risk scores
estimated risk of non-fatal or fatal CVD outcomes, while
two risk scores predicted CVD deaths. The remaining three
scores estimated risk of non-fatal or fatal stroke. The
majority of risk scores incorporated classic CVD risk
Articles retrieved from literature search (n=2,113) 
Articles retrieved from literature search (n=11) 
Full papers (n=41) 
Abstract checked (n=98) 
Excluded on the basis of title (n=2,015) 
Excluded on the basis of abstract review (n=57) 
Additional papers identified from reference list (n=2) 
Excluded on basis of full text papers (n=30) 
Papers finally included, reporting 17 risk scores (n=13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Flow of identification of included studies
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Diabetologia (2009) 52:2001–2014 2007factors, such as age, sex, smoking, blood pressure and total
cholesterol. Most risk scores derived from the general
population contained a dichotomous variable for diabetes
(yes/no) (n=8) and did not take account of diabetes-specific
risk factors, such as duration of diabetes or glycaemia.
Conversely, risk scores developed in individuals with
diabetes often included age at diagnosis, duration of
diabetes and/or a measure of glycaemic control, such as
HbA1c or fasting plasma glucose (FPG).
Evaluation of risk scores
Sixteen risk scores were evaluated in 13 different validation
cohorts. Only the Atherosclerosis Risk in Communities risk
score was not evaluated in an external validation cohort. The
majority of validation cohorts were based in Europe (n=10)
and varied in size from 112 to 5,823 individuals with
diabetes (Table 3). The 10-year cumulative incidence of
CVD varied considerably from 5% in a Chinese cohort [18]
to 45% in a British cohort [19]. The age of individuals
ranged from 18 to 75 years at baseline and median follow-up
time from 4 to 10 years. All studies validated risk scores in
patients with type 2 diabetes, including one study that
evaluated a risk score in type 1 and type 2 diabetes [20].
Individuals with diabetes were recruited from the general
population (n= 7 )o rs p e c i a l i s td i a b e t e sc l i n i c s( n=6) and
were identified through (1) computerised databases or
registries in five cohorts; (2) clinical records in seven
cohorts; and (3) from the placebo arm of a trial in one
cohort. Only three studies included a clear definition of
diabetes, e.g. whether individuals were diagnosed by FPG or
an OGTT according to WHO criteria (Table 3). Two articles
failed to include any information on how individuals with
diabetes were identified or diagnosed. Similarly, four articles
did not include a clear definition of which CVD endpoint
was used, with definitions varying between studies, e.g.
clinical diagnosis of fatal and non-fatal CVD, CHD
determined using coronary angiography or fatal CVD.
Clinical records were used to retrieve data on CVD
endpoints (n=11) in most validation cohorts and these were
confirmed by expert reviewers in two studies. Diagnosis of
CVD was made using coronary angiography in one
validation study in Greece (Table 3). The majority of
validation studies compared the performance of different
CVD risk scores in a single population (n=7). Among these,
four studies compared the predictive ability of risk scores
developed in individuals with diabetes and those developed
in a general population.
Performance of the risk scores
Table 3 summarises the measures of predictive ability
assessed in each validation study. Few studies reported
complete measures of predictive performance, including
discrimination, calibration and global model fit. The
majority of studies reported a measure of discrimination
(area under the receiver operating characteristic curve
[aROC], also known as a c-statistic). Risk scores predicting
CVD or CHD outcomes showed moderate to good
discriminatory power in validation cohorts (aROC range
0.61 to 0.80). Similarly, risk scores predicting stroke
reported aROCs from 0.59 to 0.79.
Three risk scores were evaluated using a Hosmer–
Lemeshow χ
2 statistic as a measure of calibration in two
validation cohorts, while eight studies reported either
predicted and observed event rates, predicted to observed
rate ratio or whether the scores over- or underestimated
CVD risk. Two validation studies did not report any
measure of calibration. The UK Prospective Diabetes Study
(UKPDS) risk engine showed poor calibration in both
British [19, 21] and non-British validation cohorts [18, 22],
while the Swedish National Diabetes Register [23] and
Hong Kong Diabetes Registry [18] reported good calibra-
tion in Swedish and Chinese populations respectively. Most
risk scores developed in the general population under-
estimated CVD risk in diabetic patients. We found under-
estimations ranging from 11% for fatal CVD risk using the
Diabetes Epidemiology: Collaborative Analysis of Diag-
nostic Criteria in Europe (DECODE) score [24] to 64% for
fatal and non-fatal CVD risk using the Prospective
Cardiovascular Münster (PROCAM) score [19]. Coleman
et al. validated the Framingham, Systematic Coronary Risk
Evaluation (SCORE) and DECODE risk engines in a
population of 3,898 individuals with diabetes and showed
that they did not provide reliable fatal CVD and CHD risk
estimates [24]. Conversely, in populations with low CVD
risk, such as Mediterranean countries, most of the risk
scores overestimated CVD risk, even those developed in
individuals without diabetes [22].
Studies comparing the predictive ability of a CVD risk
score developed in a diabetic cohort and a score developed
in the general population reported inconsistent results. In a
study of 339 patients with diabetes, Protopsaltis et al.
showed that the Framingham risk equations were more
accurate than the UKPDS risk engine for predicting
coronary artery disease risk (aROC 0.65 and 0.61 respec-
tively) [25]. With similar sensitivity, Framingham risk
equations had higher specificity and positive and negative
predictive values than the UKPDS risk engine (65%, 43%
and 75% vs 56%, 37% and 73%, respectively). However,
the study population was small and the diagnosis of
coronary artery disease was established by means of
coronary angiography, which includes individuals with
sub-clinical CHD, an endpoint not included in the UKPDS
definition. By contrast, in a British community-based
cohort of 428 individuals with newly diagnosed type 2
2008 Diabetologia (2009) 52:2001–2014diabetes [21], the Framingham risk equations appeared to
underestimate cardiovascular and coronary disease events
by 33% and 32%. The UKPDS risk engine had lower levels
of underestimation at 13%, suggesting that this diabetes-
specific risk score performed better than a risk score
developed in the general population. However, both the
Framingham equations and UKPDS risk engine showed
modest discriminatory ability and poor calibration (aROC
of 0.66 and 0.67, Hosmer–Lemeshow χ
2 of 19.8 [p=0.011]
and 17.1 [p=0.029] respectively), making it difficult to
reach any firm conclusions.
Sensitivity, specificity and both positive and negative
predictive values varied considerably between risk scores
and validation cohorts, although most studies reported
moderate to good sensitivity and specificity (Table 2). Risk
scores for CHD and stroke developed in the Hong Kong
Diabetes Register had good sensitivity and specificity when
tested in Chinese validation cohorts [18, 26], while the
Framingham risk score and the UKPDS risk engine also
had good sensitivity, but relatively low specificity when
tested in European populations [21, 22].
Discussion
This systematic review has shown that the predictive ability
of CVD risk scores, which were developed mainly for White
populations, varies considerably between different popula-
tions. There is little evidence to suggest that using risk scores
developed in individuals with diabetes will help to estimate
CVD risk among diabetic patients more accurately than use
of those developed in the general population. The inconsis-
tency in methods used to evaluate CVD risk scores makes it
difficult to compare or summarise the predictive ability of
different risk scores.
Our review supports previous research showing that
CVD risk scores developed in the general population are
likely to underestimate CVD risk in individuals with
diabetes [9]. In theory, one way of addressing this
underestimation would be to use risk prediction tools solely
derived from diabetic populations [10]. However, our
results suggest that diabetes-specific risk engines need to
be validated in other populations before they are widely
adopted and can replace Framingham-based methods of
risk assessment. The issue of predicting risk for people with
diabetes is likely to be increasingly complex, as a greater
proportion of patients are treated with CVD risk factor
modifying therapy. The development of risk prediction
scores in populations with long-standing and treated
diabetes, possibly incorporating information about the
degree of glycaemic control, would be an important issue
for future research. At the same time, the prediction of
absolute future CVD risk in a clinical situation is likely to
be based on single baseline measures of cardiovascular risk
factors and not on any time-averaged measures collected
during repeat visits. While the latter has a role in assessing
the aetiological association between risk factors and
outcome, repeated measures have limited utility in the
practical clinical situation of risk prediction.
Most diabetes-specific risk scores incorporate measures of
glycaemic control suchasFPG andHbA1c, while most scores
developed in the general population include a binary variable
indicating whether an individual has diabetes or not. Hence,
an important question in the general population is whether
adding measures of glycaemic control improves the predic-
tive ability of existing risk scores incorporating traditional
CVD risk factors. In populations of people with diabetes,
studies comparing the predictive performance of the Fra-
mingham risk score and the UKPDS risk engine have shown
conflicting results [21, 25]. Part of the uncertainty about the
additional predictive contribution of hyperglycaemia in this
context is explained by the fact that, in comparison with age,
cholesterol and smoking, hyperglycaemia is a relatively
weak CVD risk factor, thus making it harder to show
significantly improved prediction [27]. The differences
between studies could also be explained by changes in the
distribution of risk factors for CVD and their treatment over
time, which could differ within and between populations.
This has implications for the generalisability of a question-
naire, even within the population in which it was developed,
since by necessity the development stage of a risk score has
to take place in a different temporal period to the practical
application of the score in a clinical setting. It is conceivable
that temporal trends in risk factors and the way they are
treated could have major impacts on the predictive accuracy
of risk scores that were developed using historical data but
are applied to predict what may happen in the future.
Differences between populations in the underlying distribu-
tions of risk factors and their treatment would limit the
potential generalisability of risk scores to populations other
than that in which they were derived.
Itisalsoimportanttorecognisethatthechoiceofvalidation
population will havean influence on the performance of a risk
score in estimating CVD risk. Studies that develop risk scores
in one half of a cohort and then validate them in the other half
are likely to report better predictive abilities. This is true of
scores developed from the Hong Kong Diabetes Registry [18,
26] and the Swedish National Diabetes Register [23].
Conversely, validating risk scores in different populations
and ethnic groups is likely to result in relatively poorer
prediction. For example, the UKPDS risk engine had
moderate discrimination and poor calibration when evaluated
in a Chinese diabetic population [18]. This underlines the
fact that the accuracy of a risk score largely relies on the
background risk of a specific population to which it is
applied. It may be more useful to develop or recalibrate
Diabetologia (2009) 52:2001–2014 2009population-specific risk prediction tools, rather than trying to
find a universal risk score that will work in all populations.
This review used a comprehensive search without
language restrictions. To the best of our knowledge, it is
the first systematic review to assess the ability of risk scores
to estimate cardiovascular risk in individuals with diabetes.
We extracted data on widely used measures of predictive
accuracy, including discrimination, calibration, sensitivity,
specificity and positive and negative predictive values.
Apart from a difference in the choice of validation
population, each study had different inclusion criteria,
follow-up, ascertainment methods, definition of diabetes
and CVD endpoints. This makes it difficult to compare the
predictive ability between different risk scores and between
validation populations. The performance of CVD risk
scores varied considerably, and there is no conclusive
evidence of a difference in the predictive performance
of risk scores developed in individuals with diabetes
and of those developed in the general population. A
variety of statistical approaches was used to describe
and compare the predictive performance of the different
risk scores; our review suggests that a more systematic
and standardised approach is needed.
Methodological issues
The estimation of CVD risk is a dynamic research field and
there are a number of unresolved methodological issues
concerning the development, validation and comparison of
risk scores. It is clear from the systematic review that a
number of statistical techniques can be employed to assess
the performance of predictive models. However, these
measures are not uniformly calculated across all studies
and it is sometimes difficult to obtain a comprehensive
picture of the use of a risk score without taking all these
measures into account. Risk scores are frequently derived
using a logistic regression model, which models the log
odds of having the event during the specified follow-up
period as a function of the other variables. The estimated
coefficients from the logistic regression model are then
used to define the risk score. Although this risk estimate is
continuous, many of the methods of comparing prediction
assume that a threshold will be used to categorise people
into two groups on the basis of the risk score.
Measures of discrimination Discrimination is the ability of
the prediction model to correctly separate individuals into
those who will and those who will not have the event of
interest.The commonlyusedreceiver operatingcharacteristic
curve(ROC)isaplotofsensitivityontheverticalaxisagainst
(1−specificity) on the horizontal axis for every possible cut-
off value of the continuous risk score. The aROC is the area
under the ROC curve and is equal to the probability that a
randomly selected individual with the event has a higher
value of the risk score than a randomly selected individual
withouttheevent.Atestthatwastotallyuninformativewould
have a c value of 0.5, while a perfect test would have a c
value of 1. The discrimination of two possible models can
be compared by comparing the values of their aROCs. Net
reclassification improvement (NRI) [28] is used to compare
two models A and B, which share all risk factors except for
one new marker included in model B. After classification of
the predicted probabilities from the two models into risk
categories, the NRI is the proportion of times model B
correctly moves an individual with the event into a higher
risk category or an individual without the event into a lower
risk category, minus the proportion of times the new model
incorrectly moves an individual with the event into a lower
risk category or an individual without the event into a higher
risk category. Integrated discrimination improvement (IDI)
[28] is calculated by subtracting, for model A and B, the
average probability of the event in the individuals without
the event from the average probability of the event in the
individuals with the event, and then calculating the
difference in these two quantities. The values of NRI and
IDI are both between 0 and 1, or 0 and 100%. The higher
the values, the greater the improvement in performance of
the new model. It is possible to test whether each statistic is
significantly different from 0.
Calibration of risk scores Calibration is the extent to which
predicted risk from a model equals observed risk in the data.
The Hosmer–Lemeshow Goodness of fit test is calculated by
ordering the predicted probabilities of the event into, say, ten
nearequalsizedgroups.Theobservedandexpectednumbers
of individuals with the event within each group are then
compared using a χ
2 statistic (with nine degrees of freedom
if there are ten groups). A statistically significant result
implies that the model may be poorly calibrated.
Global measures of model fit The likelihood ratio statistic is
a global measure of model fit. The Bayesian information
criterion (BIC) and Akaike’s information criterion (AIC) are
two measures that combine both fit (as measured by the
likelihood ratio statistic) and model complexity, in terms of
numberofvariables(BICandAIC)andalso(forBIC)number
of observations. These measures can be used in the same
datasetfor model selection;comparing two models,the model
with the lower value of either BIC or AIC would be preferred.
However, as Ware [29] has demonstrated, a new marker
could be an important risk factor that significantly improves
the fit of the model, but it may have almost no impact on
model discrimination as measured by aROC.
CVD risk scores are often compared using the aROC, with
a significant increase in the aROC being taken as evidence
that the discrimination of a risk score has improved. More
2010 Diabetologia (2009) 52:2001–2014recently,Cookandothers[30, 31]h a v ea r g u e dt h a tt h ea R O C
is an insensitive measure based purely on ranks and that we
should also calculate a measure of calibration (e.g. the
Hosmer–Lemeshow statistic) and global fit (e.g. BIC) in
order to comprehensively assess the utility of a risk score.
They argue that the critical issue for clinical application is
‘the proportion of patients reclassified using a new risk
algorithm and whether the magnitude of this reclassification
is large enough to alter physician behaviour with regard to
prevention’ [31, 32]. Pepe et al. [33]r e c e n t l ys u g g e s t e d
calculating the NRI and IDI measures when comparing two
scores, in order to assess whether any reclassification was in
the right or wrong direction.
An example from our previous research illustrates some of
these analytical approaches [34]. Using data from EPIC-
Norfolk, a UK population-based prospective cohort [35], we
computed two novel risk scores by fitting Cox proportional
hazards regression models with CHD as the outcome. In
model A, we used the original Framingham risk score
variables, i.e. age, total cholesterol, HDL-cholesterol, systol-
ic blood pressure, smoking status and diabetes. In model B,
we replaced the diabetes variable with HbA1c to examine
whether the addition of this continuous variable improved
the prediction of CHD. While the results on discrimination
indicated that model B was better than model A at
distinguishing between individuals with and without the
disease, results from the NRI statistic suggested that this
difference did not significantly improve reclassification. This
conflicting information highlights the challenges of compar-
ing CVD risk scores and demonstrates that despite statistical
advances, a number of questions remain unanswered.
Most of the risk scores in this systematic review were
developed using models for censored survival time data, such
as the Cox proportional hazards model or the accelerated
failure time model. However, the most common method for
deriving the aROC is based on a logistic regression model,
which ignores the time-dependent nature of the data. New
approaches to assessing the performance of a risk score
estimatedfromsurvivaldatainthepresenceofcensoringhave
been proposed [36, 37]. These new performance measures
have been shown to be unbiased, unlike the aROC from
logistic regression, which tends to be underestimated and
have a larger standard deviation [37].
Conclusions
The computation of CVD risk is likely to remain an important
part of the process of prioritising therapy for individuals and
populations. The degree to which such risk scores can be
improvedisquestionable, asattemptstoaddnovel riskfactors
to existing CVD scores and thereby improve their predictive
abilityhavenotbeenverysuccessful[38, 39], largely because
a risk factor must be very strongly associated with a disorder
for it to be useful for prediction [40]. Few novel biomarkers
have demonstrated an ability to predict risk over and above
information available from global assessment tools such as
Framingham [38, 41]. Furthermore, there is rarely evidence
that reductions in any of these novel markers will lower
cardiovascular risk [42]. Genetic risk information currently
adds little to prediction, but may become increasingly
important in the future. However, there is little evidence that
the provision of genetic risk information is associated with
behaviour change [43].
Thus while there is clearly some scope for improving
prediction, it is likely that improvements will be marginal.
Indeed, it may be more profitable to focus on ensuring that
tools currently available for risk prediction are applied more
broadly and routinely throughout clinical practice in order to
address the gap between the promise of CVD prevention and
its reality [39]. When attempting to reduce CVD risk, the
precision of the instrument may be less important than how it
is used. As such, there is still a need for further research into
provider and patient perceptions of CVD risk. There is
considerable uncertainty on how best to present risk
information and on whether the presentation of risk
information is associated with lifestyle change or the degree
of medication adherence [44–46]. The downsides of present-
ing risk information also need to be considered. For example,
it is possible that showing how little CVD risk is reduced by
lowering blood glucose alone may discourage people from
adhering to hypoglycaemic medication.
Cardiovascular risk scores are useful tools in the
management of individuals with diabetes, particularly when
the score has been developed in a population of similar
individuals. Scores that rank risk well are appropriate for
identifying those at highest risk, to whom therapy can then
be targeted. Conversely, the process of predicting risk
accurately in order to provide prognostic information is
better aided by risk scores that accurately quantify absolute
risk. Finally, we see a potentially important role for scores
capable of quantifying that element of risk that is
modifiable, a strategy that could help motivate patients to
change. While improvement in the predictive ability of risk
scores might still be obtained, the public health utility of
their application depends on a far wider range of issues.
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Appendix
Terms and strategy used for literature search
#1 risk assessment [Mesh] #20 coronary disease
risk assessment
#39 Reynolds risk
#2 predictive value of
tests [Mesh]
#21 chd risk assessment #40 Dundee risk
#3 Sensitivity and
Specificity [Mesh]
#22 cvd risk assessment #41 brhs score
#4 Reproducibility of
Results [Mesh]
#23 heart disease risk
assessment
#42 British Family Heart
Study
#5 risk score #24 cvd risk score #43 New Zealand chart
#6 risk calculat* #25 OR/15–24 #44 seven countries study
#7 risk engine #26 framingham risk #45 Progetto CUORE
#8 risk equation #27 framingham
risk*
#46 OR/26–45
#9 risk algorithm #28 framingham
equation
#47 14 OR 25 OR 46
#10 risk chart #29 framingham model #48 cardiovascular disease
[Mesh]
a
#11 risk table #30 PROCAM #49 coronary artery disease
[Mesh]
b
#12 risk prediction #31 score #50 stroke [Mesh]
c
#13 risk functions #32 decode #51 OR/48–50
#14 OR/1–13 #33 ukpds #52 diabetes mellitus, type 2
[Mesh]
d
#15 cardiovascular risk
score
#34 copenhagen risk #53 51 AND 52
#16 cardiovascular risk
assess*
#35 British Regional
Heart Study
#54 Diabetic Angiopathies/
epidemiology [Mesh]
#17 cardiovascular risk
assessment
#36 Swedish National
Diabetes Register
#55 Diabetic Angiopathies/
etiology [Mesh]
#18 cardiovascular disease
risk assessment
#37 Tayside #56 53 OR 54 OR 55
#19 coronary risk
assessment
#38 qrisk #57 47 AND 56
a(“Cardiovascular Diseases/classification”[Mesh] OR
“Cardiovascular Diseases/complications”[Mesh] OR “Car-
diovascular Diseases/diagnosis”[Mesh] OR “Cardiovascu-
lar Diseases/epidemiology”[Mesh] OR “Cardiovascular
Diseases/etiology”[Mesh] OR “Cardiovascular Diseases/
mortality”[Mesh] OR “Cardiovascular Diseases/prevention
and control”[Mesh])
b(“Coronary Artery Disease/classification”[Mesh] OR
“Coronary Artery Disease/complications”[Mesh] OR “Cor-
onary Artery Disease/diagnosis”[Mesh] OR “Coronary
Artery Disease/epidemiology”[Mesh] OR “Coronary Artery
Disease/etiology”[Mesh] OR “Coronary Artery Disease/
mortality”[Mesh] OR “Coronary Artery Disease/prevention
and control”[Mesh])
c(“Stroke/classification”[Mesh] OR “Stroke/complica-
tions”[Mesh] OR “Stroke/diagnosis”[Mesh] OR “Stroke/
epidemiology”[Mesh] OR “Stroke/etiology”[Mesh] OR
“Stroke/mortality”[Mesh] OR “Stroke/prevention and con-
trol”[Mesh])
d(“Diabetes Mellitus, Type 2/complications”[Mesh] OR
“Diabetes Mellitus, Type 2/diagnosis”[Mesh] OR “Diabetes
Mellitus, Type 2/epidemiology”[Mesh] OR “Diabetes Mel-
litus, Type 2/mortality”[Mesh])
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